TARS - Tarsus Pharmaceuticals initiated at buy at Oppenheimer; sees 118% upside

Oppenheimer has initiated Tarsus Pharmaceuticals (TARS +1.6%) with a buy rating and a $55 price target (~118% upside). Analyst Francois Brisebois is optimistic on TP-03 (lotilaner ophthalmic solution), the company's candidate in phase 3 for the eye inflammation condition demodex blepharitis. He said he was impressed with data from several mid-stage trials. Brisebois added the company could "attack a large unmet medical need" with TP-03, and could also benefit from its early-stage pipeline. Read about mid-stage data on TP-03

For further details see:

Tarsus Pharmaceuticals initiated at buy at Oppenheimer; sees 118% upside